JP2017515901A5 - - Google Patents

Download PDF

Info

Publication number
JP2017515901A5
JP2017515901A5 JP2017511565A JP2017511565A JP2017515901A5 JP 2017515901 A5 JP2017515901 A5 JP 2017515901A5 JP 2017511565 A JP2017511565 A JP 2017511565A JP 2017511565 A JP2017511565 A JP 2017511565A JP 2017515901 A5 JP2017515901 A5 JP 2017515901A5
Authority
JP
Japan
Prior art keywords
optionally substituted
compound
aryl
heteroaryl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017511565A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017515901A (ja
JP6419313B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/030014 external-priority patent/WO2015172099A1/en
Publication of JP2017515901A publication Critical patent/JP2017515901A/ja
Publication of JP2017515901A5 publication Critical patent/JP2017515901A5/ja
Application granted granted Critical
Publication of JP6419313B2 publication Critical patent/JP6419313B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017511565A 2014-05-09 2015-05-08 抗ウイルスの化合物、医薬組成物およびその使用方法 Expired - Fee Related JP6419313B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461991418P 2014-05-09 2014-05-09
US61/991,418 2014-05-09
US201562177900P 2015-03-25 2015-03-25
US62/177,900 2015-03-25
PCT/US2015/030014 WO2015172099A1 (en) 2014-05-09 2015-05-08 Anti-viral compounds, pharmaceutical compositions, and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2017515901A JP2017515901A (ja) 2017-06-15
JP2017515901A5 true JP2017515901A5 (cg-RX-API-DMAC7.html) 2018-04-05
JP6419313B2 JP6419313B2 (ja) 2018-11-07

Family

ID=54393071

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017511565A Expired - Fee Related JP6419313B2 (ja) 2014-05-09 2015-05-08 抗ウイルスの化合物、医薬組成物およびその使用方法

Country Status (9)

Country Link
US (3) US9884876B2 (cg-RX-API-DMAC7.html)
EP (1) EP3139920A4 (cg-RX-API-DMAC7.html)
JP (1) JP6419313B2 (cg-RX-API-DMAC7.html)
CN (1) CN106456615B (cg-RX-API-DMAC7.html)
AU (3) AU2015255714B2 (cg-RX-API-DMAC7.html)
CA (1) CA2948178A1 (cg-RX-API-DMAC7.html)
MX (2) MX2016014642A (cg-RX-API-DMAC7.html)
TW (1) TW201623265A (cg-RX-API-DMAC7.html)
WO (1) WO2015172099A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019021520A2 (pt) 2017-04-14 2020-08-04 Tollnine, Inc. oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune
CA3051422A1 (en) * 2018-08-09 2020-02-09 Kineta, Inc. Activators of the retinoic acid inducible gene "rig-i" pathway and methods of use thereof
TW202035426A (zh) * 2018-08-17 2020-10-01 美商奇尼塔公司 視黃酸誘導基因"rig-i"途徑之活化劑及其使用方法
WO2020089460A1 (en) * 2018-11-02 2020-05-07 Aicuris Gmbh & Co. Kg Novel urea 6,7-dihydro-4h-thiazolo[5,4-c]pyridines active against the hepatitis b virus (hbv)
CA3139977A1 (en) 2019-06-05 2020-12-10 Raymond F. Schinazi Peptidomimetics for the treatment of coronavirus and picornavirus infections
US20220273689A1 (en) * 2019-07-09 2022-09-01 Regents Of The University Of Minnesota Potentiation of antiviral nucleobases as rna virus therapy
CN114502194A (zh) * 2019-10-02 2022-05-13 华盛顿大学 用于治疗乙型肝炎病毒感染的组合物和方法
MX2022010515A (es) 2020-02-28 2022-11-14 Tallac Therapeutics Inc Conjugacion mediada por transglutaminasa.
CA3177852A1 (en) 2020-04-04 2021-10-07 Pfizer Inc. Methods of treating coronavirus disease 2019
US12358897B2 (en) 2020-04-05 2025-07-15 Pfizer Inc. Compounds and method of treating COVID-19
US12485157B2 (en) 2020-04-05 2025-12-02 Pfizer Inc. Method of treating COVID-19
MX2021013934A (es) 2020-04-05 2021-12-15 Pfizer Compuestos y metodos para el tratamiento de covid-19.
CN115996756A (zh) 2020-05-08 2023-04-21 博尔特生物治疗药物有限公司 弹性蛋白酶底物肽连接子免疫缀合物及其用途
UY39222A (es) 2020-05-19 2021-11-30 Kallyope Inc Activadores de la ampk
CN113831301B (zh) * 2020-06-08 2023-06-06 沈阳药科大学 苯并噻唑类衍生物及其用途
EP4172162A4 (en) 2020-06-26 2024-08-07 Kallyope, Inc. AMPK ACTIVATORS
EP4178955A1 (en) 2020-07-11 2023-05-17 Pfizer Inc. Antiviral heteroaryl ketone derivatives
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
WO2022078602A1 (en) * 2020-10-15 2022-04-21 Baden-Württemberg Stiftung Ggmbh Flavi-block: a pan-flavivirus inhibitor
CN116897155A (zh) * 2021-02-24 2023-10-17 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的苯并噻唑基双环[1.1.1]戊烷衍生物
EP4314011A4 (en) * 2021-03-24 2025-01-01 Anavex Life Sciences Corp. PREVENTION AND TREATMENT OF CORONAVIRUS INFECTION
WO2022208262A1 (en) 2021-03-30 2022-10-06 Pfizer Inc. Ether-linked antiviral compounds
TWI869780B (zh) 2022-03-02 2025-01-11 美商輝瑞大藥廠 用於篩檢人類個體之呼吸疾病、監測人類個體之呼吸病況以及提供決策支援之方法及電腦化系統
WO2024149990A1 (en) 2023-01-10 2024-07-18 Oxford University Innovation Limited Nirmatrelvir analogs as 3c like protease inhibitors for treating viral infections
AU2024285970A1 (en) 2023-06-09 2025-12-11 Pfizer Inc. Solid forms of n-(methoxycarbonyl)-3-methyl-l-valyl-(4r)- n-{(1s)-1-cyano-2-[(3s)-2-oxopyrrolidin-3-yl]ethyl}-4-(trifluoromethyl)-l-prolinamide and solvates thereof
WO2025037206A1 (en) 2023-08-11 2025-02-20 Pfizer Inc. Deuterated antiviral compounds
WO2025040743A1 (en) 2023-08-22 2025-02-27 Univerza V Ljubljani Conjugated tlr7 and rig-i agonists
WO2025191272A1 (en) 2024-03-13 2025-09-18 Storm Therapeutics Ltd Inhibitory compounds
CN119707862B (zh) * 2025-02-24 2025-06-27 北京悦康科创医药科技股份有限公司 基于RLRs受体激动剂的疫苗佐剂脂质化合物、包含其的组合物及用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1024316A (en) * 1911-07-29 1912-04-23 Singer Mfg Co Strip folding and guiding attachment for sewing-machines.
JPS53129036A (en) * 1977-04-18 1978-11-10 Fuji Photo Film Co Ltd Color photographic material
JPH0780355B2 (ja) * 1987-01-22 1995-08-30 富士写真フイルム株式会社 光学的情報記録媒体
GB9923710D0 (en) * 1999-10-08 1999-12-08 Proteus Molecular Design Chemical compounds
WO2004078115A2 (en) * 2003-02-28 2004-09-16 Viropharma, Incorporated Benzothiazole compounds, compositions and methods for treatment and prophylaxis of rotavirus infections and associated diseases
WO2005037845A1 (en) * 2003-10-17 2005-04-28 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole[5,5-b] pyridine compositions and their use as ubiquitin ligase inhibitors
CA2706586A1 (en) * 2007-11-21 2009-05-28 Alan S. Florjancic Novel compounds as cannabinoid receptor ligands and uses thereof
CA2786314A1 (en) * 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2012155352A1 (en) * 2011-05-19 2012-11-22 Eli Lilly And Company Dihydroisoxazole compounds, parasiticidal uses and formulations thereof
US9555106B2 (en) * 2011-09-30 2017-01-31 Kineta, Inc. Anti-viral compounds
US9073946B2 (en) * 2013-01-15 2015-07-07 Kineta, Inc. Anti-viral compounds
CN103193770B (zh) * 2013-03-20 2015-10-28 中国人民解放军第二军医大学 取代苯并噻唑类抗真菌化合物及其制备方法与应用

Similar Documents

Publication Publication Date Title
JP2017515901A5 (cg-RX-API-DMAC7.html)
JP2013518107A5 (cg-RX-API-DMAC7.html)
JP2013032389A5 (cg-RX-API-DMAC7.html)
PH12018550201A1 (en) Hepatitis b antiviral agents
JP2014521688A5 (cg-RX-API-DMAC7.html)
BR112015014457A2 (pt) composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c
EA201891876A1 (ru) Тетрациклические пиридоновые соединения в качестве противовирусных средств
JP2015024998A5 (cg-RX-API-DMAC7.html)
JP2017537066A5 (cg-RX-API-DMAC7.html)
JP2016515561A5 (cg-RX-API-DMAC7.html)
TR201906470T4 (tr) İmmünomodülatörler.
NZ729150A (en) Antiretroviral agents
NZ631726A (en) Therapeutic compounds for the treatment of viral infections
PH12013500015A1 (en) 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
EA200901241A1 (ru) Соединения для лечения гепатита с
JP2016540742A5 (cg-RX-API-DMAC7.html)
CA2862755A1 (en) Antiviral compounds with a dibenzooxaheterocycle moiety
JOP20210249A1 (ar) مشتقات البيرميدون الحلقية المدمجة للاستخدام في علاج عدوىhbv أو الأمراض التي يسببها فيروس hbv
BR112015024552A2 (pt) compostos de fórmula (a), composição farmacêutica, métodos para a preparação do composto e métodos de tratamento ou prevenção de infecções
JP2016540749A5 (cg-RX-API-DMAC7.html)
WO2012174312A3 (en) Benzimidazole derivatives as antiviral agents
ECSP13012438A (es) Proceso para preparar compuestos antivirales
EA201490213A1 (ru) Бензофурановые соединения для лечения инфекций вирусом гепатита с
RU2017103656A (ru) Производные изоиндолинона, полезные в качестве противовирусных средств
EA201992771A1 (ru) Ингибитор поверхностного антигена вируса гепатита b